EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Iliac perivascular myeloid sarcoma presenting with iliofemoral deep vein thrombosis and hydronephrosis

Zhao Shan, Yue Wang, Honggang Wang, Jiaxuan He, Hongyi Cai

Frontiers in Oncology · 11.05.2026 · 16

DOI: 10.3389/fonc.2026.1838693 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 11.05.2026. Verfasst von Zhao Shan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital), Lanzhou, Ch…. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloid sarcoma (MS) is a rare extramedullary tumor of myeloid blasts that may occur before, concurrently with, or after acute myeloid leukemia (AML) (1–4). We report a 53-year-old man with progressive left lower-limb pain and swelling, initially admitted to the vascular surgery service, with imaging revealing left external iliac vein and proximal common femoral vein occlusive thrombosis, a peri-iliac mass encasing the iliac vessels, and ipsilateral hydronephrosis. Biopsy of the left inguinal lesion showed MPO positivity, CD34 positivity, partial TdT positivity, and a Ki-67 index of about 80%, supporting myeloid sarcoma. Bone marrow studies confirmed AML with maturation, with 55% blasts, a myeloid immunophenotype, CEBPA (TAD1) positivity, and a complex karyotype. Baseline fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) demonstrated irregular perivascular soft tissue extending from the left common to external iliac vessels, with mild FDG uptake. The patient received AML-directed therapy, including two IA cycles and high-dose cytarabine, achieving morphologic complete remission with a marked PET/CT response. During follow-up, measurable residual disease (MRD) fluctuated repeatedly despite continued morphologic remission, prompting venetoclax-based therapy, including cytarabine plus venetoclax, azacitidine plus venetoclax with homoharringtonine, and later azacitidine plus venetoclax combined with tislelizumab. At the last follow-up in December 2025, the patient remained alive. This case highlights that peri-iliac MS may mimic vascular and urologic disease and that serial MRD monitoring can be useful for guiding postremission treatment adaptation in AML with extramedullary disease.

Schlagwörter

Stichwörter der Autor:innen

PET/CTacute myeloid leukemiadeep vein thrombosismyeloid sarcomavenetoclax

Autor:innen und Institutionen

  • Department of Radiation Oncology, The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital), Lanzhou, China.
  • Department of Radiation Oncology, Dongguan Taixin Hospital, Dongguan, China.
  • Department of Ultrasound Medicine, Wuwei People's Hospital, Wuwei, China.

Zitieren

APA

Shan, Z., Wang, Y., Wang, H., He, J., & Cai, H. (2026). Case Report: Iliac perivascular myeloid sarcoma presenting with iliofemoral deep vein thrombosis and hydronephrosis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1838693

Vancouver

Shan Z, Wang Y, Wang H, He J, Cai H. Case Report: Iliac perivascular myeloid sarcoma presenting with iliofemoral deep vein thrombosis and hydronephrosis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1838693

BibTeX
@article{Shan2026,
  author = {Shan, Zhao and Wang, Yue and Wang, Honggang and He, Jiaxuan and Cai, Hongyi},
  title = {Case Report: Iliac perivascular myeloid sarcoma presenting with iliofemoral deep vein thrombosis and hydronephrosis},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1838693}
}
Kostenlos starten →